Non small cell lung cancer treatment with carboplatin and vindesine: a phase II study.
A phase II trial aiming to verify the effectiveness of a regimen including carboplatin and vindesine was performed. From November 1989 to September 1990, nineteen patients with advanced small cell lung cancer entered this study. Polychemotherapy treatment included: carboplatin 400 mg/sm, on day 1 and vindesine 3 mg/sm, on days 1 and 15, repeated every 4 weeks, as an outpatient regimen. Observed toxicity was mild; myelodepression, and nausea and vomiting were the main adverse events. No objective response was obtained; 14 no changes in the disease and 4 progressions were detected. The low objective response rate observed in this study is strongly influenced by a set of unfavourable prognostic factors. The median overall survival time [32 weeks] is comparable with the results of other studies.
Bretti
S
S
Ospedale San Giovanni Antica Sede, Dipartimento di Oncologia, Torino, Italy.
Bonardi
G M
GM
Celano
A
A
Comandone
A
A
Casadio
C
C
Marchisio
U
U
Forconi
G
G
Manzoni
S
S
Bumma
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D016190:Carboplatin / Q000008:administration & dosage / Q000633:toxicity*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D014751:Vindesine / Q000008:administration & dosage / Q000633:toxicity*
D016190:Carboplatin; D014751:Vindesine